
-
Ironwood Pharmaceuticals NasdaqGS:IRWD Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Location: 100 Summer Street, Boston, MA, 02110, United States | Website: https://ironwoodpharma.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
592.8M
Cash
108.5M
Avg Qtr Burn
N/A
Short % of Float
7.16%
Insider Ownership
2.53%
Institutional Own.
97.46%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Linzess® (linaclotide) Details Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder | Approved Quarterly sales | |
Linzess® (linaclotide) Details Constipation | Approved Quarterly sales | |
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome (SBS) with intestinal failure (IF) | Phase 3 Update | |
IW-3300 Details Endometriosis, Visceral pain, Interstitial cystitis/bladder pain syndrome | Phase 2 Data readout | |
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome with colon-in-continuity , Short bowel syndrome | Phase 2 Update | |
Apraglutide (agonist of the GLP-2 receptor) Details Acute graft-versus host disease | Failed Discontinued | |
CNP-104 Details Primary biliary cholangitis, Liver disease, Autoimmune disease | Failed Discontinued | |
Linaclotide Details Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation | Failed Discontinued |